Company EXACT Therapeutics

Equities

EXTX

NO0010852213

Biotechnology & Medical Research

Business Summary

Sales per Business

Sales per region

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

Sales per region

Sector Other Biotechnology & Medical Research

Real-time Oslo Bors Other stock markets 08:15:00 28/06/2024 pm IST			5-day change	1st Jan Change
7.4 ^NOK	-.--%		-.--%	-38.33%

19/04	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study	MT

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Number of employees: 12

NOK in Million	2022	Weight	2023	Weight	Delta
Acoustic Cluster Therapy 100.0 %	0	100.0 %	0	100.0 %	-99.02%

NOK in Million	2022	Weight	2023	Weight	Delta
Norway 100.0 %	0	100.0 %	0	100.0 %	-99.02%

Managers	Title	Age	Since
Svein Kvåle FOU	Founder	-	01/12/01
Per Walday CEO	Chief Executive Officer	64	28/22/28
John Edminson DFI	Director of Finance/CFO	-	01/22/01
Amir Snapir CTO	Chief Tech/Sci/R&D Officer	-	21/22/21
Ragnar Bendiksen CTO	Chief Tech/Sci/R&D Officer	50	-
Johan Caspar Foghsgaard PRN	Corporate Officer/Principal	-	01/11

Members of the board	Title	Age	Since
William Castell BRD	Director/Board Member	76	22/18/22
Ann-Tove Kongsnes BRD	Director/Board Member	57	-
Masha Paule Nathalie Strømme BRD	Director/Board Member	53	01/15/01
Anders Wold CHM	Chairman	-	03/21/03

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	32,080,552	10,360,704 ( 32.30 %)	0	32.30 %

Name	Equities	%	Valuation
Svein Kvåle 9.427 %	3,024,270	9.427 %	2 M kr
Masha Paule Nathalie Strømme 8.390 %	2,691,509	8.390 %	2 M kr
Investinor AS 7.443 %	2,387,750	7.443 %	2 M kr
Brekke Holding AS 7.405 %	2,375,628	7.405 %	2 M kr
Andrew John Healey 6.875 %	2,205,385	6.875 %	2 M kr
Hagen Stein Erik Family 6.300 %	2,021,000	6.300 %	1 M kr
Per Christian Sontum 5.990 %	1,921,605	5.990 %	1 M kr
Optimuspistor AS 4.909 %	1,574,750	4.909 %	1 M kr
Nordea Investment Management AB (Norway) 3.881 %	1,244,994	3.881 %	912 867 kr
Else Helene Sundt 3.526 %	1,131,000	3.526 %	829 283 kr

EXACT Therapeutics AS

?stre Aker vei 19

0581, Oslo

http://exact-tx.com

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
EXACT THERAPEUTICS	-38.33%	2.23Cr
MODERNA, INC.	+19.41%	4.55TCr
IQVIA HOLDINGS INC.	-8.62%	3.85TCr
LONZA GROUP AG	+38.82%	3.81TCr
ALNYLAM PHARMACEUTICALS, INC.	+26.95%	3.07TCr
CELLTRION, INC.	-13.50%	2.6TCr
ICON PUBLIC LIMITED COMPANY	+10.74%	2.59TCr
UNITED THERAPEUTICS CORPORATION	+44.87%	1.41TCr
MEDPACE HOLDINGS, INC.	+34.36%	1.27TCr
BIO-TECHNE CORPORATION	-7.14%	1.13TCr

Other Biotechnology & Medical Research